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Prevention of calcium stones with thiazides
EDMUND R. YENDT and MOUSSA COHANIM
Department of Medicine, Queen's University and Kingston General Hospital, Kingston, Ontario, Canada
In 1962, we began a clinical trial designed to assess
the efficacy of the thiazide diuretics in the prevention
of calcific urinary calculi. During the subsequent 15
years, we have initiated thiazide therapy in 346 pa-
tients. We have also conducted a series of investiga-
tions designed to clarify the mechanism by which
thiazides prevent stone growth.
Hypocaiciuric action of thiazides
The initial rationale for the use of thiazides in
stone prevention was based on the observation that
thiazide diuretic therapy resulted in reduced urinary
excretion of calcium, an effect first reported by Lam-
berg and Kuhlback in 1959 [1] and subsequently
confirmed by a number of investigators [2—51. The
hypocalciuric effect usually begins within two to
three days of starting the drug [5], is usually maximal
within six days, and is nearly always sustained. The
magnitude of the reduction in urine calcium excre-
tion is variable, but with the dose of hydrochiorothia-
zide usually employed by us (50mg twice daily), the
mean reduction in urine calcium excretion is 150 mg/
day, and in patients with hypercalciuria the urine
calcium has been seen to decrease by as much as 400
mg/day. Occasionally, the decrease is much less pro-
nounced, and in a small percentage of normal sub-
jects and patients, there is little discernible effect. It
should be emphasized that this hypocalciuric effect
is unique to thiazide diuretics and related drugs, such
as chlorthalidone and metolazone, whereas other
commonly used diuretics either have no significant
effect on calcium excretion (e.g. spironolactone,
triamterene), or they produce hypercalciuria (e.g.
furosemide, ethacrynic acid).
The mechanism by which thiazides reduce urinary
calcium excretion has engaged the attention of a
number of investigators but is still not entirely clear.
We have found that diazoxide, a member of the
thiazide family which lacks a natriuretic effect, does
not possess the hypocalciuric action in man, suggest-
ing that the hypocalciuria is related in some way to
the natriuresis. At the site in the nephron where
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chlorothiazide exerts its primary effect (probably the
cortical diluting site of the distal nephron), there is a
dissociation between sodium transport and calcium
transport, and at this site chlorothiazide selectively
inhibits sodium reabsorption without a concomitant
inhibition of calcium reabsorption [61. Subsequent
studies in dogs have suggested that thiazides might
actually enhance distal tubular calcium reabsorption,
and they also have demonstrated that the dissocia-
tion between sodium and calcium clearance is not
dependent upon volume depletion, because the re-
sponse is rapid and also because the effect is unilat-
eral when the drug is injected into one renal artery
[71. Moreover, this acute effect is not dependent
upon the presence of parathyroid hormone since it
occurs in parathyroidectomized dogs if sufficient
drug is infused to correct for the reduced tubular
secretion of chlorothiazide which follows parathy-
roidectomy [7].
The hypocalciuric response to chronic thiazide
administration in man appears to be somewhat more
complicated. This response is blocked if volume de-
pletion is prevented by sodium chloride administra-
tion [8,9], which suggests that it may be dependent
on enhanced sodium reabsorption (and calcium sec-
ondarily) by the proximal tubule in response to vol-
ume depletion. Moreover, the hypocalciuric re-
sponse in man appears to be blunted or absent in
some hypoparathyroid patients, which has prompted
the suggestion that the presence of parathyroid hor-
mone is a prerequisite for thiazide-induced hypocalci-
uria [9—1]. This conclusion, however, is difficult
to reconcile with the reports that thiazides reduce
urinary calcium excretion in parathyroidectomized
rats [12,13]. Furthermore, we have demonstrated a
marked hypocalciuric response to thiazides in the
occasional hypoparathyroid patient. Thiazide admin-
stration does not increase the serum levels of para-
thyroid hormone [14—16] or the urinary excretion of
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cyclic AMP [11]; in fact, serum PTH levels may
decrease in hypercalciuric patients during thiazide
administration [151. It has been postulated that thia-
zides may potentiate the action ofparathyroid hormone
by inhibiting phosphodiesterase, an enzyme which
accelerates degradation of cyclic AMP [171.
Other thiazide ejfrcts on calcium metabolism
The effect of thiazides on the intestinal absorption
of calcium is a matter of considerable importance: it
has a bearing on thiazide-induced changes in skeletal
function and urine oxalate excretion, and it also has a
bearing on the possibility that chronic thiazide ther-
apy might induce metastatic calcification. There ap-
pears to be no consistent effect of acute thiazide
administration on intestinal calcium absorption. A
review of five papers which record thiazide-induced
changes in fecal calcium in 34 patients indicates that
fecal calcium may be diminished, unchanged, or in-
creased during the initial days of thiazide administra-
tion [2, 5, 18—20). There are a number of possible
explanations for the divergent results. The first is
that there may be a true individual difference in the
actue effect of thiazides on intestinal calcium absorp-
tion depending upon the nature of the underlying
disorder and the state of total body calcium reserves.
Another possibility is that the divergent results may
be related in part to differences in drug dosages
employed by different investigators. A third possibil-
ity is that the conflicting results may be a reflection of
the methodologic problems associated with conven-
tional calcium balance studies. We have reported
some evidence which confirms the initial reduction in
fecal calcium excretion observed in the majority of
our balance studies [5]. In one of our patients, whose
fecal calcium fell by 44% initially during thiazide
treatment, radioactive calcium (47Ca) was injected
i.v. during the control period and again during the
period of drug administration [5]. The recovery of
the administered tracer dose in the stools and the
calculated endogenous fecal calcium was consider-
ably less in the treatment period than in the control
period.
Although the acute effects of thiazides on intes-
tinal calcium absorption appear to be somewhat con-
troversial, there is fairly good evidence, though
based on limited studies, that intestinal calcium ab-
sorption may decrease during long-term thiazide ad-
ministration. In two patients with idiopathic hyper-
calciuria, we repeated calcium balance studies after
10 months' and 38 months' treatment in one patient
and after eight and 21 months' treatment in the other.
In the first patient, in whom there had been an initial
decrease in fecal calcium in response to thiazide
administration, fecal calcium excretion had risen to
the pretreatment level eight months later, despite a
slightly reduced calcium intake; but after 38 months,
fecal calcium exceeded pretreatment values by 238
mg/day (Fig. 1). In the second patient, in whom there
had been no significant initial effect of thiazides on
fecal calcium excretion, fecal calcium excretion had
increased by 51 mg/day after 21 months but not after
eight months' therapy, and calcium balance was no
longer positive at the time of the last study [5]. A
similar sequence of events has been observed in one
of three osteoporotic patients during long-term thia-
zide administration [20]. Ehrig, Harrison, and Wil-
son [211, using a double isotopic technique, have
studied intestinal calcium absorption during long-
term thiazide in 22 patients with recurrent calcium
stones. After three to 16 months' therapy, calcium
absorption was significantly decreased in 10 patients
and unchanged in 12. However, in six of the 12
patients in whom calcium absorption was un-
changed, the repeat studies were done after only four
months' treatment, and it is quite possible that
changes would have been observed in these patients
as well if the studies had been carried on for longer
periods of time. These studies should be extended to
more patients, with various forms of calcium uroli-
thiasis, including absorptive and renal hypercalci-
urias. It would be of some interest to determine if the
reduction in intestinal calcium absorption during
thiazide therapy is generalized, or if it is characteris-
tic of only certain forms of calcium urolithiasis.
We have also investigated the effects of thiazides
on bone turnover in patients with stone disease and
osteoporosis, using calcium kinetic techniques. In
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Fig. 1. Calcium balance studies in a patient (male) svith recurrent
calcium stones prior to and during thiazide therapy. In January,
1966, after 38 months on treatment, fecal calcium (open bars)
exceeded pretreatment values by 238 mg per day. The values for
urinary (solid bars) and fecal (open bars) calcium excretion are the
mean values for the entire 16 days' pretreatment period and for the
entire 12 days of each of the three different treatment periods.
Each calcium balance study was preceeded by an eight-day equi-
librium period on the constant diet.
Nov. 62
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these studies, the patients with stone disease demon-
strated an initial decrease in bone resorption which
was followed some months later by reduced bone
formation, so that eventually the entire process of
bone turnover appeared to be significantly dimin-
ished; the three osteoporotic patients demonstrated
similar results 12011. This appears to be another exam-
ple of the close coupling of bone formation and bone
resorption [22], a finding which had been demon-
strated previously with other agents that suppress
bone resorption [23, 24]. Thus, there appears to be
strong evidence that although significant amounts of
calcium may be retained by the body during the
initial periods of thiazide administration, there is
eventually a return to a state of zero calcium
balance.
The effect of thiazides on urinary hydroxyproline
excretion, an index of bone resorption, provide fur-
ther confirmatory evidence for the general conclu-
sion arrived at above. We have consistently
observed a one-third reduction in urinary
hydroxyproline excretion during thiazide therapy
[25]. The urinary excretion of hydroxyproline also
decreases during thiazide administration in the rat
[26]. In rats pretreated with 45Ca, the concentration,
and the specific activity of 45Ca in the bones are
significantly higher in the thiazide-treated animals
than in controls, suggesting that the breakdown of
bone mineral and bone matrix is reduced during
thiazide administration. 126].
There is some confusion in the literature concern-
ing the effects of thiazides on serum calcium concen-
trations. During the first few days of thiazide admin-
istration, there is frequently a slight rise in total
serum calcium concentrations to the upper limit of
the normal range or even to levels slightly above the
normal range [5]. This is due to hemo-concentration
(with a resultant rise in the protein-bound fraction of
the blood calcium) which can be demonstrated if the
ultrafiltrable (non-protein-bound) fraction of the
serum calcium is measured simultaneously (Fig. 2).
For the past eight years, we have measured the
calcium concentrations in the serum ultrafiltrate, in
addition to total blood calcium concentrations, in our
thiazide-treated patients at yearly intervals. Al-
though a rise of the serum ultrafiltrable calcium con-
centration within the normal range is sometimes ob-
served, elevations above the normal range have been
found in only six patients, and this change may not
become evident until a year or more has elapsed. The
degree of hypercalcemia is usually slight and is
thought to represent an unmasking of normocalcemic
hyperparathyroidism by thiazides. Three of the six
patients underwent parathyroidectomy which cor-
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Fig. 2. Total and ultrafiltrable serum calcium values prior to and
during thiazide therapy in a patient having idiopathic hypercalci-
uria. There is a temporary rise in total serum calcium values above
the normal range during the first few days of thiazide therapy due
to hemoconcentration, but there is no significant change in ultra-
filtrable calcium values.
rected the hypercalcemia. Single parathyroid adeno-
mas were removed in two patients; in the third, all
four parathyroid glands appeared grossly normal at
the time of surgery, and two glands and a portion of a
third which were removed appeared histologically
normal. The remaining three patients who developed
hypercalcemia during thiazide therapy have shown
no progression of their stone disease and appear to
be suffering no ill effects from their mild
hypercalcemia.
Our experience with respect to thiazide-induced
changes in serum calcium concentrations is compa-
rable to that of Jorgensen, Transbol, and Binder,
who noted a similar increase in total serum calcium
concentrations during the first five days of thiazide
administration but were unable to demonstrate any
significant thiazide-induced increase in the serum
concentrations of ultrafiltrable or ionized calcium in
10 normocalcemic stone patients and 10 hypercal-
cemic patients with hyperparathyroidism [27].
Duarte et al reported one patient whose total serum
calcium concentration rose from 10 to 12.4 mgIlOO
ml on the ninth day of thiazide treatment and then
fell to normal by the 14th day; however, serum
ultrafiltrable calcium remained at control levels
throughout the entire period [28]. Stote et al found
that both total and ionized calcium concentrations
were significantly increased during administration of
hydrochlorothiazide and for at least two weeks after
withdrawal of the drug [16]. The maximum mean
serum ionized calcium concentration reported in
12 -
Total
S
S
E
=
U
0
11
10
9
8
7
6 - Ultrafiltrable
400 Yendt and Cohanim
their study, however, was 4.05 mg!100 ml (an in-
crease of 0.42 mg/100 ml above control levels), which
occurred on the 17th day of drug administration; this
value probably lies within the normal range, although
the authors did not provide this information in their
paper.
Although the danger of thiazides inducing signifi-
cant hypercalcemia is remote in the patient with
normal calcium metabolism, this may not be so if the
patient has a disease associated with increased bone
resorption, such as malignancy, primary hyperpara-
thyroidism, sarcoidosis, immobilization, Paget's dis-
ease, etc. In such instances, thiazides may induce
hypercalcemia or aggravate pre-existing hypercal-
cemia and should be used with extreme caution [291.
Thiazides have been reported to cause parathyroid
enlargement and hyperplasia in the dog [301, but the
doses used in these experiments were much greater
on a weight-to-weight basis than those given to hu-
mans. Parathyroid hyperplasia, however, did not oc-
cur during chronic thiazide administration in rats
[31], and there is no good evidence that thiazides
induce parathyroid hyperactivity or increased sensi-
tivity to parathyroid hormone in man. As previously
mentioned, there is no evidence of increased para-
thyroid hormone secretion during thiazide adminis-
tration to humans [14— 16] and serum PTH levels
may, in fact, diminish in hypercalciuric patients dur-
ing thiazide administration 115]. Moreover, our ob-
servations previously referred to, of diminished urine
hydroxyproline excretion and decreased bone turn-
over during thiazide administration, are incompatible
with increased production of parathyroid hormone or
increased skeletal sensitivity to it. It is acknowl-
edged, however, that the effects on bone were as-
sessed principally from kinetic analysis but not by a
direct histological examination of bone or by a quan-
titative measurement of bone mineral content.
Effect of thiazides on other urinary constituents
Although the hypocalciuric action of thiazides
prompted its initial use for stone prevention, it now
appears likely that there are other thiazide-induced
changes in the composition of urine which are of
equal or greater significance with regard to stone
prevention. Perhaps the best known of these effects
is the 20 to 30% increase in urinary magnesium
excretion which is evident during the initial period of
thiazide administration. The magnesium ion is
known to block the calcification of organic matrix in
vitro [321! and to enhance the solubility of calcium
oxalate in vitro 1331. There are, however, conflicting
data as to the duration of the increased urinary mag-
nesium excretion. We found that this effect was still
evident in two of our patients who were studied on
the same diet, 10 months and 22 months after thia-
zide therapy was begun [5]. Moreover, in a group of
our patients having stone disease, studied under ad
lib dietary conditions, urine magnesium excretion
still exceeded pretreatment levels after two years'
thiazide therapy [34]. Others have reported that in-
creased urine magnesium is no longer evident after
five days [351 or after one month [36]. We believe,
however, that at least in some patients, increased
loss of magnesium in the urine probably persists for
many years, because we have observed that serum
magnesium levels may gradually decline for as long
as seven years after thiazide therapy is started.
A less well known thiazide effect is a marked
increase of approximately 50% in urinary zinc excre-
tion [37, 381 which is sustained during long-term
thiazide therapy [39]. Zinc is a potent inhibitor of
calcification in vitro; calcification of rachitic rat carti-
lage is partially inhibited when physiologic concen-
trations of zinc (0.1 mM) are added to the incubating
medium in the absence of magnesium, but calcifica-
tion is completely blocked when a minute amount of
magnesium, insufficient by itself to affect the system,
is added [40]. If the calcification of rachitic rat carti-
lage bears any relationship to the formation of cal-
cific renal calculi, which also consist of calcium salts
deposited in an organic matrix, this effect may con-
tribute to the efficacy of thiazides in preventing cal-
cium stone. If, on the other hand, stone formation is
largely a matter of precipitation of crystalloids from
supersaturated solutions and matrix is purely inci-
dental, the significance of these findings is less cer-
tain. Zinc has been shown to have little if any inhibi-
tory effect on the crystallization of calcium oxalate
from a supersaturated solution [41]; however, the
concentration of zinc used in these experiments
(0.005 mM) was at the extreme lower limit of the
range found to be effective in retarding calcification
of rachitic rat cartilage, and the possibility of a syner-
gistic effect of the magnesium ion was not explored.
At the moment, therefore, the significance of the
increased urinary zinc excretion remains uncertain.
The effect of thiazides on urine oxalate excretion
may prove to be of great importance in stone preven-
tion. In 1971 it was reported that a marked decrease
in urine oxalate excretion occurred with the adminis-
tration of 50 mg of hydrochlorothiazide daily [42]. In
1973, we reported that we did not find urine oxalate
changes of a similar magnitude, although we did
observe a small but significant reduction in urine
oxalate excretion in 39 thiazide-treated patients [431.
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Others, however, reported no significant effect of
thiazides on urine oxalate excretion [44] (Rose, per-
sonal communication).
Recent observations reported from our laboratory
confirm that there is a significant reduction in urine
oxalate during chronic thiazide therapy, and they
also shed some light on the divergent results reported
by different workers [45]. We have measured urine
oxalate before and during hydrochlorothiazide ther-
apy in 54 patients with recurrent calcium stones.
Although no significant reduction in urine oxalate
excretion occurred during the first year of treatment,
a significant reduction in urine oxalate excretion was
observed in 36 of 47 patients treated for more than 12
months (Fig. 3). In the latter group, urine oxalate
excretion during therapy was 15 1.8 mg/24 hr
(mean sEM) as compared to pretreatment values of
32 3.3 mg/24 hr (Fig. 4).
The striking similarity in the time patterns noted
for the thiazide-induced reduction of urine oxalate
excretion and of intestinal calcium absorption leads
us to believe the two changes are related. This possi-
bility is strengthened by the demonstration that the
absorption of dietary oxalate bears an inverse rela-
tionship to the amount of free calcium in the intes-
tinal lumen [46]. It seems likely, therefore, that dur-
ing long-term thiazide therapy more dietary oxalate
is precipitated as insoluble calcium oxalate in the
intestinal lumen because of reduced intestinal cal-
cium absorption, and thus less oxalate is excreted in
the urine. The magnitude of the reduction in oxalate
excretion which we have observed is potentially of
great clinical significance since relatively small
changes in urinary oxalate concentrations may have
a marked effect upon the calcium oxalate activity
product of urine, whereas changes in urine calcium
concentration are believed to be of much less impor-
tance in this regard [47].
Thiazide administration frequently results in slight
or modest reduction in urine citrate excretion [48],
an effect which is possibly secondary to potassium
depletion [49]. This is the only thiazide-induced ef-
fect which we have observed which could theoreti-
cally aggravate stone formation. In view of the effi-
cacy of thiazides in stone prevention, it is obviously
of little importance.
Although some patients treated with thiazides
have noted increased thirst and fluid intake, 24-hr
urine volumes during treatment for the group as a
whole do not differ significantly from control values
[34]. A temporary increase in urinary inorganic
phosphate excretion is characteristic of the initial
period of thiazide administration, but control levels
are achieved by the 9th day [48]. The urinary excre-
tion of pyrophosphate, which has been shown to
vary directly with orthophosphate excretion [50],
also undergoes a temporary increase during the ini-
tial period of thiazide administration, but control
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Fig. 3. Urinary oxalate and calcium excretion in 51 patients
having stone disease who had been taking thiazides for 12 to 96
months. Each symbol indicates the difference between the ob-
served values during treatment and the pretreatment values for the
same patient.
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Fig. 4. Urine oxalate excretion in patients with calcium stones,
before and during thiazide therapy. A significant reduction in urine
oxalate excretion occuned after but not during the first year of
treatment.
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levels are achieved within one month [36]. Although
thiazides alter the renal tubular handling of urate,
there is no change in the absolute amount of uric acid
excreted in the urine. Thus, there is no danger with
thiazide of inducing formation of stones of uric acid
or calcium oxalate [34, 48] (C0E, this issue). Thia-
zides have been shown also to decrease the urinary
saturation with respect to brushite [36] and calcium
oxlate [51] in the majority of patients.
Treatment regimen
All members of the thiazide group of diuretics and
related drugs such as chiorothalidone and metola-
zone possess a hypocalciuric effect. There is no
evidence to suggest that any one of this group of
drugs is more effective than another in stone preven-
tion, although there is a paucity of information on
this subject. The drug employed by us in nearly all
our patients has been hydrochiorothiazide, and we
have usually employed only one brand (Hydrodi-
uril®, Merck, Sharp and Dohme) to avoid possible
variations in potency and absorption.
The standard dose of hydrochiorothiazide em-
ployed by us is 50 mg, twice daily. In some of our
early unreported work on this subject, it was found
that this dose usually produced the maximum hypo-
calciuric response, whereas smaller doses often
failed to achieve this effect. At the present time, one
half the usual dose of hydrochiorothiazide (i.e., 50
mg daily) has been prescribed for 33 patients. Al-
though this reduced dose appears to be adequate for
some patients, we have seen a number of patients
who continued to form stones on 50 mg per day but
not on 100 mg per day. A major difficulty with regard
to dosage is that there are no good data relating
biochemical response to therapeutic efficacy. Stone
formation appears to cease in some patients despite a
minimal hypocalciuric response, and as previously
indicated, other thiazide-induced changes in the bio-
chemical composition of the urine such as reduced
urine oxalate excretion may prove to be just as im-
portant or more important in this regard.
To minimize the incidence and severity of thia-
zide's side effects, which are frequently more severe
during the first few weeks of treatment, we no longer
initiate therapy with the maximum dose of hydro-
chlorothiazide but start with 25 mg of hydrochioro-
thiazide daily for one week and increase the daily
dose by 25 mg at weekly intervals until the mainte-
nance dose of 50 mg twice daily is achieved.
It has not been our practice to restrict dietary
calcium, oxalate, or sodium chloride in thiazide-
treated patients, but excessive intakes of these di-
etary constituents is corrected. Potassium supple-
ments are not provided as a routine, but patients are
provided with an information sheet which outlines
the need for an increased intake of potassium-con-
taining foods and emphasizes the importance of cor-
recting potassium deficiency in the event of heart
disease, digitalis therapy, or prior to the administra-
tion of a general anaesthetic. Potassium supplements
are provided to patients with symptoms of potassium
deficiency and to asymptomatic patients when serum
potassium levels fall below 3.0 mEq/liter.
Before any therapeutic program is initiated, it is
important to establish the radiologic status of the
patient, with respect to the presence or absence of
stones, as precisely as possible. If this is not done, it
may be difficult to determine whether stone recur-
rences during treatment have resulted from progres-
sion of the stone problem or from stones which were
previously present. In this regard, we have often
found that the routine plain film of the abdomen or
the i.v. pyelogram is frequently of such poor quality
that the presence or absence of stone cannot be
established with certainty, and for this reason, renal
tomography without dye injection is frequently ad-
visable. Patients who are treated with thiazides for
stone prevention should be advised to return for
follow-up studies within the first six months of treat-
ment, and then, at annual intervals; in the occasional
patient more frequent follow-up may be advisable.
At the time of these visits, appropriate radiologic
assessment, urinalysis, urine culture, and serum
biochemistries are performed as a matter of routine.
Serum potassium and uric acid concentrations
should be done for obvious reasons, and the serum
calcium should also be checked because of the possi-
bility that thiazides may unmask hyperpara-
thyroidism.
Efficacy of thiazides
In 1970, we reported the results of our first five
years' experience with the use of thiazides in the
prevention of calcium stone in 72 patients [341. We
divided our patients into two groups. Group I was
composed of patients who had no stone in situ when
treatment started, and group 11 comprised 34 patients
with radiologic evidence of renal stones when ther-
apy was begun. In the group I patients, stone epi-
sodes decreased from 0.57 per patient year to 0.03
per patient year during 72 patient years of treatment;
only two patients had further stone formation (one
stone each) during 64 patient years of treatment. In
the group II patients, stone episodes decreased from
1.1 per patient year to 0.53 per patient year; most of
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the stone episodes during treatment resulted from
stones which were in the urinary tract when treat-
ment started, and there was evidence of new stone
formation in only four patients.
In 1973, we reported ten years' experience with
this mode of treatment [431. Duringthe period 1962—
1972, thiazide therapy was initiated in 197 patients.
Of these, 19 were lost to follow-up, and thiazides
were discontinued in 39, leaving 139 patients who
remained on long-term treatment with adequate fol-
low-up. Stone progression (i.e., formation of new
stones or growth of stones present when treatment
started) occurred in only eight patients with nonin-
fected stones who had adhered strictly to the treat-
ment regimen during approximately 700 patient years
of treatment. At least six of these eight patients,
however, were improved on thiazides and continued
to take thiazides. In an additional seven patients,
stone formation was arrested during thiazide therapy
but was resumed after they had discontinued thia-
zides or decreased the dose.
At the time of writing, thiazide therapy has been
initiated in 346 patients with renal calculi. Progres-
sion of stone disease has been identified in 16 pa-
tients taking a full dose of hydrochlorothiazide in
whom compliance was considered to be excellent.
Progression has also occurred in six additional pa-
tients for whom a full dose of the drug was pre-
scribed, but in whom compliance was extremely
poor. Of the 33 patients for whom only one half the
usual dose of hydrochiorothiazide was prescribed,
progression has occurred in four patients whose
complicance was good and two patients whose com-
pliance was poor.
The clinical histories of the 16 patients in whom
there has been evidence of stone progression during
thiazide treatment are depicted in Figure 5. A possi-
ble or probable explanation for stone progression was
identified in three of these patients. Patient number
15 was a case of hypoparathyroidism with marked
hypercalciuria due to treatment with pharmacologic
doses of vitamin D and supplemental calcium; uri-
nary calcium fell by less than 10% during thiazide
therapy, and it is not surprising that stone formation
continued under these circumstances. In case #1027,
growth of one stone occurred in association with a
Staphylococcus albus urinary tract infection; when
the infection was eradicated, no further progression
occurred during the subsequent three and one half
years of thiazide therapy. In case #1162, stone pro-
gression occurred only at the time when the patient
took his hydrochlorothiazide in one daily dose in-
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Fig. 5. The stone histories of 16 patients in whom there has been stone progression during thiazide treatment. These represent all the
treatment-failures identified in patients taking a full dose of hydrochiorothiazide in whom compliance was good. The figures in the column
separating the pretreatment and treatment data indicate the number of renal calcifications seen on X-ray when treatment started. The
bracketed figures following the treatment data indicate the number of renal calcifications seen at the time of last follow-up. There is some
uncertainty that stone progression has occurred in cases #1178 and #1245, because the X-rays taken when treatment began are not of
adequate quality to rule out the presence of stones at that time. A probable explanation for stone progression was identified in cases TI. 15,
#1027, and #1162 (see text). During the treatment period, only the circled events were due to new stone formation.
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TabIc 1. Urine composition before and during thiazide in treatment-failure patients
Urine volume Urine creatinine Urine calcium Urine magnesium
Patient
no. Sex Diagnosisa
mn1124 hr tng/24 hr mg/24 hr mg/24 hr
Before DuringBefore During Before During Before During
TA 131 M IH 1547 1730 2143 2360 440 205 156 143
TU 1 M IH 3420 3110 2080 1790 713 443 87 54
TU2 M IH 1300 1400 1810 1830 346 309
150 (yr 1)
88 124
TC66 M IS 1487 1484 1871 2076 311 268(yr2)
306 (yr 3)
167 111
1010 M IH 1430 1934 2080 2121 557 223 155 179
1169 M TE 1865 2585 1617 1798 559 301 85 119
t2t2 M Is 2125 19t0 t770 1893 299 168 142 121
1322 M TE 3020 2710 2470 2447 757 366 45 89
1449 M TE 1115 1822 1915 1991 466 353 63 87
1641 M TE 1300 1110 1935 1645 311 193 145 90
1710 M TE 1107 1330 1833 1942 455 259 97 135
Mean 5EM 1792 232 1920 191 1957 69 1990 74 474 48 270 28 112 13 114 10
a Abbreviations used are: IH, idiopathic hypercalciuria; IS, idiopathic stone-former; TE, tubular ectasia.
ND means 'not done."
stead of two divided doses as instructed; the hypo-
calciuric response to thiazide was considerably di-
minished during that period of time. Two additional
patients, case #1178 and case #1245, are included
for the sake of completeness, although we are uncer-
tain that stone progression occurred during thiazide
treatment in either of them, because the X-rays taken
when treatment was initiated are of such poor quality
that stones may well have been present at that time.
In the remaining 11 patients, we are confident that
stone progression has occurred during thiazide ther-
apy, and there is no obvious explanation for the
treatment failures. The clinical and biochemical data
in these patients are summarized in Table 1. The
group consists entirely of male patients, and the
incidence of tubular ectasia which was present in five
of the 11, is considerably higher than in the treatment
group as a whole; moreover, some of our earlier
patients diagnosed as having idiopathic hypercalci-
uria or idiopathic calcium stones might also have had
tubular ectasia, because it is only in recent years that
we have made an intensive search for ectatic tubules
in patients having stone disease. The mean 24-hr
urine volume, creatinine, calcium, oxalate, phos-
phate, and uric acid for the group was significantly
greater than for normal male subjects studied under
similar conditions, but the 24-hr urinary excretion of
magnesium, citrate, zinc, and sodium did not differ
significantly from normal (Table 2). Of greater inter-
est, perhaps, is a comparison of these 11 patients
with 31 consecutive male hypercalciuric stone pa-
tients who have been treated successfully with thia-
zides (Table 2). The urinary excretion of calcium,
phosphorous, and uric acid was greater in the treat-
ment-failure group, but no other significant differ-
ences were observed. Thus, a greater degree of hy-
percalciuria is characteristic of the treatment-failure
group than in hypercalciuric male patients success-
fully treated with thiazides, and in addition urine
phosphorous and uric acid excretions were signifi-
cantly greater than normal, which was not the case in
the successfully treated group of patients. The in-
creased urinary excretion of uric acid in the treat-
ment failure group is of particular interest in view of
the report of Coe and Kavalach that stone formation
ceased in all but two of 27 patients with idiopathic
hypercalciuria and associated hyperuricosuria during
combined thiazide and allopurinol treatment [52]. In
their report, hyperuricosuria was defined as a 24-hr
urinary uric acid excretion in excess of 800 mg in
male patients on unrestricted diets; 24-hr urinary uric
acid excretion exceeded 800 mg in 9 of the 11 pa-
tients in our treatment-failure group and in 13 of the
31 patients sucessfully treated with thiazides. The
upper limit of normal for urinary uric acid excretion
in our normal male subjects studied on unrestricted
diet on the ambulant basis, however, is 1065 mg/24
hr, and on this basis most of these patients would be
more properly classified as having uric acid excretion
in the high normal range rather than as true hyperuri-
cosurics. These remarks emphasize the potential im-
portance of hyperuricosuria in the pathogenesis of
calcium oxalate stones (Coe, this issue).
The biochemical response to thiazide administra-
tion in the 11 patients who continued to form stones
during thiazide treatment is seen in Table 1. The
thiazide-induced changes in urinary calcium, oxa-
late, and citrate excretion were qualitatively and
quantitatively similar to those observed in the treat-
ment group as a whole.
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Table 1 (continued). Urine composition before and during thiazide in treatment-failure patients
Urine oxalateb Urine phosphorush Urine citrate Urine uric acidb Urine zinc' Urine sodiumb
mg/24 hr mg124 hr mg124 hr ,ng124 hr p.g/24 hr
—
mEqI24 hr
Patient Before During Before During Before During Before During Before During Before During
TA 131 47 ND5 ND ND 265 301 946 1056 ND ND ND ND
TU 1 27 ND 1090 ND 248 132 951 ND ND ND ND ND
TU 2 36 ND 1134 ND 520 381 890 927 ND ND ND ND
TC66 48 36 ND 785 226 151 591 801 ND ND ND ND
1010 ND 33 1170 1138 699 724 834 847 ND 1310 ND 195
1169 55 12 1155 1200 375 192 1042 985 450 1079 122 199
1212 26 27 1285 1099 427 273 1019 644 1072 1292 229 328
1322 ND ND 1457 1249 590 319 1648 1191 1579 1900 256 220
1449 33 ND 924 823 240 228 765 805 ND 882 ND 248
1641 34 16 1022 877 591 359 816 709 430 463 177 258
1710 20 22 923 1186 680 497 848 973 393 771 151 202
Mean 36±4 24±4 1124±641045±66 442±55 323± 51 941± 80 894± 52 785±235 1099± 175 187± 25 263± 31
There is a commonly held misconception that for stone formation in any of these patients during 103
patients having calcium stones, the use of thiazides patient years of observation. A total of 10 stone
should be restricted to patients with hypercalciuria. episodes occurred in five patients after thiazides
For some years now, we have stated that this mode were begun, but in every instance these episodes
of therapy is equally effective in normocalciuric pa- were due to stones which were present when therapy
tients. We have not previously reported, however, was instituted. Another most interesting feature evi-
the data on which this opinion is based. The clinical dent from this study, one that we have not previously
histories of 28 normocalciuric patients with calcium commented on, is that there was, during treatment, a
stones before and during thiazide therapy are de- reduction in the number of renal calcifications evident
picted in Figure 6. There was no evidence of new on X-ray in eight patients who had not experienced
Table 2. Biochemical composition of urine
Stone patients with progression Stone patients with no
Normal male subjects on thiazides5 progression on thiazides
(male, hypercalciuric)
Mean SEM P Mean SEM P Mean SEM
Volume, m1124 hr 1269 103 <0.025 1792 232 NS 1761 120
N 31 11 31
Creatinine, mg124 hr 1796 58 <0.05 1957 69 NS 1882 52N 30 11 31
Calcium, mg124 hr 221 16 <0.0005 474 48 <0.05 396 13
N 29 11 31
Magnesium, mg124 hr 93 7 NS 112 13 NS 111 7
N 16 11 31
Oxalate, mg124 hr 18 3 <0.0005 36 4 NS 31 4
N 14 9 29
Phosphorus, mg/24 hr 932 41 <0.01 1124 64 <0.025 1007 43N 21 9 30
Citrate, mg124 hr 521 52 NS 442 55 NS 487 49
N 16 11 29
Uric acid, mg124 hr 761 39 <0.05 941 80 <0.025 780 32N 16 1! 30
Zinc, jzgI24 hr 587 30 NS 785 235 NS 685 50
N 29 5 18
Sodium, mEqI24 hr 174 13 NS 187 25 NS 190 7
N 27 5 27
a Most 24-hr urine specimens were collected on an out-patient basis on unrestricted diets. Patients values are pretreatment values.
b The urine composition of the individual patients in this group is described in Table 1.
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renal colic and who were unaware of having passed
gravel or stones during the treatment period.
It will be noted from Figure 6 that in 17 of the 28
normocalciuric patients successfully treated with
thiazides some degree of tubular ectasia (medullary
sponge kidney) was evident in the i.v. pyelogram.
Stone progression has also ceased in 30 hypercal-
ciuric patients with tubular ectasia who were treated
with thiazides.
We have previously referred to the fact that the
failure to observe the usual degree of hypocalciuric
response following the initiation of thiazide therapy
does not necessarily signify that thiazides will be
ineffective in stone prevention. We are following a
small group of 10 patients who fall into this category
who have shown no evidence of stone progression
during 42 patient years of treatment.
Our favourable experience with the use of thia-
zides in stone prevention has been confirmed by Coe
and Kavalach who reported new stone formation in
only two of 37 patients with idiopathic hypercalciuria
during 740.5 months of treatment with trichlorme-
thiazide (4 mg/day) [52]. Rose and Harrison report
that they have a very strong clinical impression that
renal stone formation has not progressed in patients
with idiopathic hypercalciuria in whom the control of
urinary calcium has been achieved and maintained
[531.
Side effects
The incidence of side effects in thiazide-treated
patients is in the order of 30 to 35% [34]. These tend
to be most severe during the initial phase of thiazide
therapy and frequently disappear with the passage of
time. In an earlier report, we indicated that side
effects necessitated discontinuation of thiazide ther-
apy in approximately 10% of our patients [43]. As a
result of two changes in our treatment regimen, how-
ever, it has been necessary to discontinue thiazide
because of side effects in only 16 or our last 225
patients. The first of these changes is the practice of
initiating thiazide therapy with a small dose and in-
creasing dosage gradually until the maintenance dose
is achieved. The second measure is to reduce the
dose of hydrochlorothiazide to 25 mg twice daily if
side effects are a problem; this usually results in
disappearance or marked reduction in the severity of
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TE
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Major stone surgery
Basket extraction
Silent stones on X-ray
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Many
Fig. 6. Clinical histories of 28 normocalciuric stone patients befbre and during thiazide treatment, in which the out-patient 24-hr urine
calciu,n values measured on unrestricted diets did not exceed300 mg in males or 250mg in females. Theflgures in the column separating the
pretreatment and treatment data indicate the number of renal calciflcations seen on x-ray when treatment started. The bracketed figures
following the treatment data indicate the number of renal calcilications seen at the time of last follow-up. There was no evidence of stone
progression during treatment in any of these patients; the episodes which occurred during treatment were all due to stones which had been
present when treatment started. In cases #1070, 1165, 1276, 1396, 1486, 1494, and 1511, a significant reduction in the number of renal
calcification occurred during treatment despite the fact that the patients were unaware of having passed stones to account for this.
Abbreviations of diagnoses are the same as in Figure 5.
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symptoms, and in most cases stone growth has not
resumed as a result of the dose reduction.
Weakness, fatigue, loss of energy and lassitude,
frequently accompanied by mental irritability and an
increased need for sleep are by far the most common
thiazide side effects and are most often those which
necessitate the discontinuation of this form of treat-
ment. These symptoms are sometimes related to
potassium deficiency and may be relieved by the
provision of potassium supplements, but in other
cases they are not alleviated by the correction of
hypokalemia. Other side effects which have necessi-
tated termination of treatment include skin rashes,
severe headaches, dizziness, mental depression, loss
of libido, and pancreatitis. Gout has developed in a
few of our patients, but in this situation it has been
our practice to add allopurinol to the therapeutic
regimen rather than discontinue thiazides. The de-
velopment of diabetes during thiazide therapy does
not necessitate discontinuation of therapy, but thia-
zide-induced hypokalemia should be corrected by
the provision of potassium supplements.
A gradual decline in serum magnesium levels has
occurred in a few patients during chronic thiazide
therapy. The lowest level which we have observed is
a total serum magnesium concentration of 1.04 mg/
100 ml (normal range, 1.60—2.45 mg/100 ml) with a
corresponding decrease in the serum ultrafiltrable
magnesium concentration to 0.56 mg/l00 ml (normal
range, 1.05—1.55 mg/100 ml). So far, we have not
observed any clinical disturbances attributable to
this biochemical abnormality. Nonetheless, this find-
ing is obviously a matter of concern; now it seems
advisable to measure serum magnesium at intervals
during long-term thiazide therapy, and the provision
of magnesium supplements may sometimes be
necessary.
There is also a possibility that long-term thiazide
treatment may induce zinc deficiency in a few pa-
tients as a result of the sustained increase in urine
zinc excretion associated with this form of therapy.
We have found serum zinc concentrations below the
normal range (85 to 135 g/100 ml) in eight of our
patients, the lowest value recorded to date being 62
gI100 ml. In this patient, the serum zinc concentra-
tion decreased gradually but remained within the
normal range for the first five years of treatment. No
untoward effects of the low serum zinc concentra-
tions have been detected in any of these patients.
We have never encountered metastatic calcifica-
tion during chronic thiazide therapy, and we are
unaware of any reports of this complication in the
medical literature. The fact that the positive calcium
balance following the institution of thiazide therapy
is only a temporary phenomenon suggests that there
need be no fear of this theoretical danger. There is no
evidence that metastatic calcification is responsible
for the induction of pancreatitis.
Selection of patients
The decision to institute thiazide therapy in a pa-
tient with recurrent calcium stones is not always an
easy one. The first consideration is whether the se-
verity of the stone problem warrants the institution
of a program of drug administration which will likely
be lifelong, and the second is the choice between
available agents of known efficacy. At the present
time, there does not appear to be an overwhelming
consensus among stone experts with respect to
either question. We are of the opinion that the asso-
ciation of hypertension and recurrent calcium stones
nearly always warrants treatment with thiazide if
diseases such as primary hyperparathyroidism and
renal tubular acidosis have been excluded. In the
normotensive patient, the decision to embark on an
effective prophylactic program is based on several
considerations, including 1) the frequency of stone
recurrence, 2) the history of major stone surgery, 3)
the presence or absence of renal calcifications, and
4) the patient's reaction to the possibility of further
stone episodes. If on the basis of these considera-
tions, an effective prophylactic regimen is war-
ranted, the choice of an agent is at the present time
largely a matter of personal preference. It is our
current practice to begin treatment with a thiazide
and to switch to orthophosphates if the patient is
unable to tolerate the drug. As has been previously
pointed out, we do not believe that the presence or
absence of hypercalciuria should have a bearing on
this decision, since thiazides are effective in both
normocalciuric and hypercalciuric patients. More-
over, we do not believe that it is necessary to distin-
guish between absorptive and renal hypercalciuria,
because thiazides are effective in both situations.
The association of hyperuricosuria with hypercalci-
uria does not in our opinion warrant combined allo-
purinol-thiazide therapy at the outset, since approxi-
mately 40% of our male hypercalciuric patients
successfully treated with thiazide treatment fall
within this category; our findings indicate, however,
that most thiazide treatment failures may be found
within this group of patients, and in such cases the
addition of allopurinol may prove beneficial at some
future time. Gout and diabetes are not absolute con-
traindications to the use of thiazides for stone pre-
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vention. A number of our patients who have devel-
oped gout prior to or during thiazide therapy are
being successfully treated with the combination of
allopurinol and a thiazide. Furthermore, the adminis-
tration of a thiazide is not likely to aggravate the
severity of diabetes if thiazide-induced hypokalemia
is corrected. In the patient with suspected primary
hyperparathyroidism, there is a preference for the
use of thiazides which might unmask the disorder,
whereas orthophosphates would tend to mask the
disorder; in other patients the low cost and conve-
nience of thiazides must be balanced against the
probability of fewer immediate side effects with
phosphates.
Summary
On the basis of almost 15 years of experience with
thiazide treatment in 346 patients with calcium
stones, we believe that the following conclusions are
justified: 1) Stone progression ceases in at least 90%
of patients who take hydrochlorothiazide (50 mg,
twice daily) on a regular basis. 2) A reduced dose of
hydrochlorothiazide, i.e., 25 mg twice daily, appears
to be effective in a significant proportion of patients.
3) Thiazides are effective in normocalciuric as well
as hypercalciuric patients and in most patients with
tubular ectasia (medullary sponge kidney). 4) Side
effects necessitate discontinuation of thiazide treat-
ment in approximately 7% of patients. The incidence
and severity of side effects is reduced by initiating
treatment with a small dose and by increasing the
dose progressively until the full maintenance dose is
achieved. A trial with a reduced dose is warranted in
patients who are unable to tolerate the regular main-
tenance dose. 5) The therapeutic efficacy of thia-
zides in stone prevention cannot be accurately pre-
dicted by the degree of hypocalciuric response.
Stone prevention may cease despite a minimal hypo-
calciuric response, whereas stone progression may
occur when an adequate hypocalciuric response has
taken place. 6) In addition to the hypocalciuric ac-
tion, thiazides reduce urine oxalate excretion and
increase urine zinc and (probably) magnesium; these
effects probably contribute to the efficacy of this
agent in stone prevention.
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